Results 71 to 80 of about 650,104 (308)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. [PDF]

Mol Oncol
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Gordon N, Gallagher PT, Richter OI, Poudel Neupane N, Mandigo AC, McCann JJ, Dylgjeri E, Vasilevskaya I, McNair C, Paller CJ, Kelly WK, Knudsen KE, Schiewer MJ, Shafi AA.   +13 more
europepmc   +2 more sources

A FOXC2 inhibitor, MC-1-F2, as a therapeutic candidate for targeting EMT in castration-resistant prostate cancer

, 2022
Androgen deprivation therapy (ADT) is the major treatment option for advanced prostate cancer. However, prostate cancer can develop into androgen-independent castration-resistant prostate cancer (CRPC) which is resistant to ADT.
Jihyun, Oh, Jiyong, Lee, Maria, Castaneda, Liandra, Rodriguez, Hanna, Suh   +4 more
core   +1 more source

Heat Shock Protein 90: From Molecular Chaperone Function to Therapeutic Targeting in Malignancies

Advanced Science, EarlyView.
In this review, an integrated conceptual framework linking HSP90's molecular chaperone functions to its pathological roles in cancer is proposed. HSP90 serves as a central node that integrates oncogenic signaling, buffers proteotoxic stress, maintains cancer stem cell plasticity, and shapes tumor‐immune interactions, all of which converge to drive ...
Beibei Zhang, Xinxin Zou, Jiansong Zhou, Qinmiao Sun, Dahua Chen   +4 more
wiley   +1 more source

Castration-Resistant Lgr5+ Cells Are Long-Lived Stem Cells Required for Prostatic Regeneration

Stem Cell Reports, 2015
The adult prostate possesses a significant regenerative capacity that is of great interest for understanding adult stem cell biology. We demonstrate that leucine-rich repeat-containing G protein-coupled receptor 5 (Lgr5) is expressed in a rare population
Bu-er Wang, Xi Wang, Jason E. Long, Jeff Eastham-Anderson, Ron Firestein, Melissa R. Junttila   +5 more
doaj   +1 more source

Identification of kinases regulating prostate cancer cell growth using an RNAi phenotypic screen. [PDF]

PLoS ONE, 2012
As prostate cancer progresses to castration-resistant disease, there is an increase in signal transduction activity. Most castration-resistant prostate tumors continue to express the androgen receptor (AR) as well as androgen-responsive genes, despite ...
Hilary Whitworth, Shriti Bhadel, Melissa Ivey, Mark Conaway, Andrea Spencer, Ronald Hernan, Heather Holemon, Daniel Gioeli   +7 more
doaj   +1 more source

177Lu-PSMA and 177Lu-DOTATATE Therapy in a Patient with Metastatic Castration-Resistant Prostate Cancer and Neuroendocrine Differentiation

, 2019
We presented a promising result of radionuclide therapy using 177Lu-PSMA and 177Lu-DOTATATE in a patient with prostatic adenocarcinoma and neuroendocrine differentiation. Functional imaging of somatostatin receptors in patients with metastatic castration-
Elahe Pirayesh, Iraj Nabipour, Amini,, A, Hojjat Ahmadzadehfar, Esmaili,, A, Zohrabi,, F, Pirayesh,, E, Farshad Zohrabi, Jafari,, E, Nabipour,, I, Abdolhamid Esmaili, Rekabpour,, S.J, Esmail Jafari, Abdullatif Amini, Seyed Javad Rekabpour, Ahmadzadehfar,, H, Majid Assadi, Assadi,, M   +17 more
core   +1 more source

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide [PDF]

, 2013
Enzalutamide, previously known as MDV300, is an oral, second-generation androgen receptor (AR) signaling inhibitor or antagonist that was approved by the Food and Drug Administration in 2012 for the treatment of metastatic castrate-resistant prostate ...
Joelle El-Amm, Jeanny B. Aragon-Ching, Nihar Patel, El-Amm, Joelle, Patel, Nihar, Aragon-Ching, Jeanny B., Ashley Freeman, Freeman, Ashley   +7 more
core   +1 more source

Cholesterol‐Mediated Metabolic‐mechanotransductive Crosstalk Orchestrates Castration Resistance in Prostate Cancer

Advanced Science, EarlyView.
Full androgen deprivation (FAD) induces paracrine cholesterol in prostate cancer that drives the polarization of cancer‐associated fibroblasts (CAFs) and subsequent elevated matrix stiffness. Matrix stiffness in turn potentiates tumor cell survival under FAD pressure via dual mechanotransductive activation of the IRE1α‐XBP1s stress‐response axis ...
Shaojie Liu, Chao Xu, Jun Jiang, Limin He, Yike Zhou, Zhengxuan Li, Yu Li, Keying Zhang, Fa Yang, Tong Lu, Hongtao Song, Hai Zhu, Zhihao Hu, Xiaolong Zhao, Kai Gan, Hongji Li, Bo Yang, Rui Zhang, Weihong Wen, Donghui Han, Weijun Qin   +20 more
wiley   +1 more source

Targeting the HSPA8‐CMA‐ATP6V1A Axis Triggers Lysosomal Hyperacidification and Catastrophic Vacuolation in Prostate Cancer

Advanced Science, EarlyView.
Our experimental evidence supports a model in which ALO targets the HSPA8‐CMA‐ATP6V1A axis to induce lysosomal hyperacidification and initiate osmotic and lipidomic stress. These changes are associated with LMP and loss of lysosomal integrity in prostate cancer cells.
Bingzheng An, Ze Gao, Shuo Chen, Liwei Meng, Chen Zhang, Kefan Song, Haochen Cui, Lei Yan, Zhiqing Fang   +8 more
wiley   +1 more source

Clinical Development of Cabazitaxel for the Treatment of Castration-Resistant Prostate Cancer

Clinical Medicine Insights: Oncology, 2011
Castration resistant prostate cancer has historically been considered chemotherapy insensitive. However, the approval of estramustine phosphate, mitoxantrone, and docetaxel, over the past few decades, has challenged this notion.
Che-Kai Tsao, Sonia Seng, William K. Oh, Matthew D. Galsky   +3 more
doaj   +1 more source